Global statistical data shed light on an alarming trend that every year thousands of people
die due to adverse drug reactions as each individual responds in a different way to the same …

Pharmacogenetics covers the genetic variation affecting pharmacokinetics and
pharmacodynamics, and their influence on drug-response phenotypes. The genetic …

Background Methotrexate (MTX) is an important component of the therapy for childhood
acute lymphoblastic leukemia. Treatment with high‐dose MTX often causes toxicity …

Background Methotrexate (MTX) eradicates leukemic cells by disrupting de novo nucleotide
biosynthesis and DNA replication, resulting in cell death. Since its introduction in 1947, MTX …

Background: To avoid severe hematotoxicity in patients, determination of the TPMT
(thiopurine S-methyltransferase) genotype before commencing thiopurine therapy has …

Abstract Background Mercaptopurine (6-MP) plays a pivotal role in treatment of childhood
acute lymphoblastic leukemia (ALL); however, interindividual variability in toxicity of this …

Lymphohematopoietic neoplasia are one of the most common types of cancer induced by
therapeutic and environmental agents. Of the more than 100 human carcinogens identified …

Dear Editor, Methotrexate (MTX) inhibits several enzymes in folate metabolic pathway,
including dihydrofolate reductase, thymidylate synthase (TYMS), and …

Drug metabolism/disposition and transporter genes may influence predisposition or
prognosis of AML (acute myeloid leukemia) patients. We analyzed polymorphisms in 3 …

Despite improvements in treatment of different types of leukemia, not all patients respond
optimally for a particular treatment. Some treatments will work better for some, while being …